QuidelOrtho Corporation (QDEL)
Why QuidelOrtho (QDEL) Could Beat Earnings Estimates Again
QuidelOrtho (QDEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QDEL continues to witness growth on the back of its strong product portfolio.
QuidelOrtho Unveils Results Manager System to Streamline Testing
QDEL introduces the Results Manager System, a powerful tool designed to streamline diagnostic data management, enhance efficiency, and improve patient care.
Why QuidelOrtho Stock Bounced More Than 4% Higher Today
Healthcare in vitro diagnostics company QuidelOrtho (QDEL 4.28%) attracted the right kind of attention from investors after posting its latest quarterly earnings report on Thursday. A rather encouraged market traded the company's shares up by more than 4% in response.
QuidelOrtho Stock Gains Following Q4 Earnings Beat, Margins Contract
Despite solid performances by the Labs and Immunohematology units and China and Other regions, QDEL reports soft overall top-line results in fourth-quarter 2024.
QuidelOrtho Corporation (QDEL) Q4 2024 Earnings Call Transcript
QuidelOrtho Corporation (NASDAQ:QDEL ) Q4 2024 Results Conference Call February 12, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and Chief Executive Officer Joe Busky - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research Patrick Donnelly - Citi Bill Bonello - Craig-Hallum Lu Li - UBS Andrew Cooper - Raymond James Casey Woodring - JPMorgan Andrew Brackmann - William Blair Jose Ricardo - RBC Capital Markets Operator Welcome to the QuidelOrtho Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast. At this time, all participant lines are in a listen-only mode.
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates
QuidelOrtho (QDEL) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $1.17 per share a year ago.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QDEL continues to witness growth on the back of its strong product portfolio.
QuidelOrtho Stock Down Despite Solid Preliminary Q4 Revenues
QDEL's preliminary fourth-quarter revenues align with the company's expectations.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QDEL continues to witness growth on the back of its strong product portfolio.
QuidelOrtho Stock Rises as Q3 Earnings & Revenues Beat Estimates
QDEL's third-quarter results reflect growth in non-respiratory revenues along with a lowering of operating expenses year over year. However, the gross margin declines in the reported quarter.
QuidelOrtho Corporation (QDEL) Q3 2024 Earnings Call Transcript
QuidelOrtho Corporation (NASDAQ:QDEL ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Juliet Cunningham – Vice President, Investor Relations Brian Blaser – President and Chief Executive Officer Joe Busky – Chief Financial Officer Conference Call Participants Andrew Brackmann – William Blair Jack Meehan – Nephron Research Bill Bonello – Craig-Hallum Patrick Donnelly – Citi Andrew Cooper – Raymond James Jose Ricardo Moreno – RBC Capital Markets Casey Woodring – JPMorgan Operator Welcome to the QuidelOrtho Third Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participant lines are in a listen-only mode.
